stockrowShattuck Labs, Inc.
STTK Healthcare Biotechnology
Shattuck Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, down 82.5% from fiscal 2024.
- Revenue
- −10.3%
- EPS
- +50.0%
- Free cash flow
- +1.01%
Quarter to June 2026, against a year earlier
Follow STTK
Alert me
Shattuck Labs, Inc. (STTK) EV/Sales
As of 6 November 2026, Shattuck Labs, Inc. (STTK) trades at a EV/Sales of 69.1×. Over the past ten years it has ranged from −66.2× (September 2023) to 501× (June 2021); the current reading is higher than 71% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 31.4× | — |
| FY2024 | −2.0× | — |
| FY2023 | 116× | — |
| FY2022 | −1.8× | — |
| FY2021 | 3.0× | (93.84%) |
| FY2020 | 48.0× | 3,446.11% |
| FY2019 | 1.4× | 0.00% |
| FY2018 | 1.4× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2025 | 15.4× | — |
| Dec 2024 | −2.0× | — |
| Sep 2024 | 13.6× | (42.47%) |
| Jun 2024 | 23.6× | (80.87%) |
| 17 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PRTCY PureTech Health PLC Sponsored ADR compare | −9.1× |
| ARVN Arvinas, Inc. compare | −0.5× |
| MNPR Monopar Therapeutics Inc. compare | n/m |
| EPRX Eupraxia Pharmaceuticals Inc. compare | n/m |
| MDXG MiMedx Group, Inc compare | 1.2× |
| GYRE Gyre Therapeutics, Inc. compare | 3.5× |
| CTMX CytomX Therapeutics, Inc. compare | 10.9× |
| STTK Shattuck Labs, Inc. | 69.1× |
| ETRA Electra Therapeutics Inc. compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)